Skip to main content

Table 3 Test positivity and HRP-2 levels by study visit

From: Persistence of Plasmodium falciparum HRP-2 antigenaemia after artemisinin combination therapy is not associated with gametocytes

 

Treatment group

N

RDT positve (%)

Ultra sensitive RDT positive (%)

HRP-2 positive (%)

HRP-2 concentration (pg/mL), median (IQR)

p-value

Adjusted p-value

0

ACT

50

40 (80)

46 (92)

46 (92)

 > 2800 (2704.3– > 2800)

0.597

0.944

ACT + PQ

50

45 (90)

49 (98)

47 (94)

 > 2800 (> 2800– > 2800)

2

ACT

50

31 (62)

44 (88)

41 (82)

1469.6 (538.2– > 2800)

0.375

0.679

ACT + PQ

49

39 (79.69)

46 (93.9)

44 (89.8)

 > 2800 (582.2– > 2800)

7

ACT

50

26 (52)

42 (84)

38 (76)

197.3 (69.3–400.8)

0.210

0.453

ACT + PQ

48

30 (62.5)

44 (91.7)

35 (72.9)

393.3 (53.1–2056.2)

14

ACT

49

15 (30.6)

29 (59.2)

21 (42.9)

40.7 (26.4–1600.6)

0.552

0.957

ACT + PQ

48

21 (43.8)

38 (79.2)

22 (45.8)

43.05 (26.3–229.6)

21

ACT

44

9 (20.5%)

22 (50)

9 (20.5)

32.6 (25.8–46.6)

0.871

0.577

ACT + PQ

46

15 (32.69%)

32 (69.6)

11 (23.9)

28.05 (24.8–49.7)

28

ACT

45

5 (11.1%)

12 (26.7)

4 (8.9)

26.6 (23.9–32.6)

0.503

0.479

ACT + PQ

45

9 (20%)

15 (33.3)

8 (17.8)

26.4 (23.9–30.5)

35

ACT

45

2 (4.4%)

7 (15.6)

3 (6.7)

23.9 (23.7–27.5)

0.217

0.154

ACT + PQ

45

5 (11.1%)

12 (26.7)

2 (4.4)

25.3 (23.7–32.6)

42

ACT

44

0 (0%)

5 (11.4)

1 (2.3)

23.9 (23.7–25.8)

0.419

0.414

ACT + PQ

45

0 (0%)

5 (11.1)

2 (4.4)

23.9 (23.7–27.5)

49

ACT

44

0 (0%)

2 (4.5)

0 (0)

23.9 (23.7–26.4)

0.253

0.365

ACT + PQ

45

0 (0%)

5 (11.1)

0 (0)

23.9 (< 6.8–26.4)